Table 2.

Incidence of adverse events and/or adverse drug reactions in any treatment group

	Placebo group (n = 39)			Topiroxostat 120-mg group (n = 39)			Topiroxostat 160-mg group (n = 40)			Allopurinol group (n = 39)
	Adverse event	Adverse drug reaction		Adverse event	Adverse drug reaction		Adverse event	Adverse drug reaction		Adverse event	Adverse drug reaction
Number of subjects	29	15		28	8		25	7		23	10
Incidence (%)	74.4	38.5		71.8	20.5		62.5	17.5		59.0	25.6
χ 2 test	P vs. 120	P vs. 160	120 vs. 160	P vs. Allo	120 vs. Allo	160 vs. Allo	P vs. 120	P vs. 160	120 vs. 160	P vs. Allo	120 vs. Allo	160 vs. Allo
P	0.799	0.257	0.379	0.150	0.234	0.748	0.082	0.038*	0.733	0.225	0.591	0.379

Incidence (%) number of adverse events- and/or adverse drug reaction-observed subjects/number of subjects for safety evaluation

*P < 0.05